These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36164841)

  • 1. A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab.
    Russo F; Cortonesi G; Lazzeri L; Taddeucci P; Rubegni P
    Dermatol Ther; 2022 Nov; 35(11):e15859. PubMed ID: 36164841
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis.
    Karstarli Bakay OS; Kacar N
    Dermatol Ther; 2022 Sep; 35(9):e15638. PubMed ID: 35703106
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-IL-23 treatment with tildrakizumab can be effective in omalizumab-refractory chronic spontaneous urticaria: A case series.
    Bonnekoh H; Kiefer L; Buttgereit T; Kolkhir P; Lütke-Eversloh M; Scheffel J; Maurer M; Metz M
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2578-2580.e1. PubMed ID: 37244440
    [No Abstract]   [Full Text] [Related]  

  • 4. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 5. Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis.
    Holm JG; Sørensen JA; Thomsen SF
    Int J Dermatol; 2022 May; 61(5):e173-e174. PubMed ID: 34813086
    [No Abstract]   [Full Text] [Related]  

  • 6. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders?
    Asero R
    Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic spontaneous urticaria refractory to cyclosporine add-on omalizumab successfully treated with methotrexate add-on.
    Garbayo-Salmons P; Expósito-Serrano V
    Dermatol Ther; 2020 Nov; 33(6):e14469. PubMed ID: 33112010
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
    Maurer M; Ensina LF; Gimenez-Arnau AM; Sussman G; Hide M; Saini S; Grattan C; Fomina D; Rigopoulos D; Berard F; Canonica GW; Rockmann H; Irani C; Szepietowski JC; Leflein J; Bernstein JA; Peter JG; Kulthanan K; Godse K; Ardusso L; Ukhanova O; Staubach P; Sinclair R; Gogate S; Thomsen SF; Tanus T; Ye YM; Burciu A; Barve A; Modi D; Scosyrev E; Hua E; Letzelter K; Varanasi V; Patekar M; Severin T;
    Lancet; 2024 Jan; 403(10422):147-159. PubMed ID: 38008109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligelizumab for Chronic Spontaneous Urticaria.
    Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
    N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab re-treatment rates in chronic spontaneous urticaria.
    Khan S; Sholtysek S
    Eur Ann Allergy Clin Immunol; 2020 May; 52(4):187-189. PubMed ID: 32378397
    [No Abstract]   [Full Text] [Related]  

  • 11. Omalizumab serum levels predict treatment outcomes in patients with chronic spontaneous urticaria: A three-month prospective study.
    Ghazanfar MN; Bartko EA; Arildsen NS; Poulsen LK; Jensen BM; Enevold C; Holm JG; Woetmann A; Ødum N; Thomsen SF
    Clin Exp Allergy; 2022 May; 52(5):715-718. PubMed ID: 35278253
    [No Abstract]   [Full Text] [Related]  

  • 12. Validation of UAS7 among children with chronic spontaneous urticaria.
    Gabrielli S; Mulé P; Prosty C; Gooding G; Le M; Zhang L; Netchiporouk E; Baum S; Greenberger S; Ensina LF; Lovett A; Zhang X; Ben-Shoshan M
    J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1927-1929.e1. PubMed ID: 35272072
    [No Abstract]   [Full Text] [Related]  

  • 13. Ligelizumab for the treatment of chronic spontaneous urticaria.
    Wedi B
    Expert Opin Biol Ther; 2020 Aug; 20(8):853-861. PubMed ID: 32380864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab for chronic urticaria.
    Casale TB
    J Allergy Clin Immunol Pract; 2014; 2(1):118-9. PubMed ID: 24565785
    [No Abstract]   [Full Text] [Related]  

  • 15. Current and Future Approaches in Management of Chronic Spontaneous Urticaria Using Anti-IgE Antibodies.
    Orzan OA; Popa LG; Mihai MM; Cojocaru A; Giurcăneanu C; Dorobanțu AM
    Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligelizumab for chronic spontaneous urticaria.
    Sabroe RA
    Br J Dermatol; 2020 Nov; 183(5):829-830. PubMed ID: 32002982
    [No Abstract]   [Full Text] [Related]  

  • 17. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems.
    Sánchez J; Alvarez L; López JF
    Actas Dermosifiliogr; 2024 Jan; 115(1):T88-T90. PubMed ID: 37871896
    [No Abstract]   [Full Text] [Related]  

  • 18. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems.
    Sánchez J; Alvarez L; López JF
    Actas Dermosifiliogr; 2024 Jan; 115(1):88-90. PubMed ID: 36754254
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria.
    Moussa S; Netchiporouk E
    Lancet; 2024 Jan; 403(10422):118-119. PubMed ID: 38008108
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of additional treatment for chronic spontaneous urticaria refractory to treatment - A single-center retrospective real-world study.
    Ohata M; Oda Y; Washio K; Fukunaga A; Nishigori C
    J Dermatol; 2022 Jan; 49(1):e7-e8. PubMed ID: 34632611
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.